Summary
Synopsis
Pentoxifylline 1 (oxpentifylline) is an orally active haemorheological agent for the treatment of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation. Pentoxifylline acts primarily by increasing red blood cell deformability, by reducing blood viscosity and by decreasing the potential for platelet aggregation and thrombus formation. Extensive open and placebo-controlled studies have shown that pentoxifylline 600 to 1200 mg/day for at least 6 weeks is associated with subjective and objective improvements in 60 to 100% of patients with peripheral vascular disease. The most commonly assessed clinical parameter, walking distance, is usually improved by about 100%, although much greater improvements have also been documented. Other parameters which have been clearly improved include lower limb rest pain, paraesthesia, muscle blood flow, cramps and leg ulcers. Pentoxifylline has produced consistently better results than placebo, and in those studies using comparative drugs, better results than nylidrin, adenosine and naftidrofuryl.
In patients with cerebrovascular disorders, open studies with pentoxifylline, usually at a dosage of 600 to 1200 mg/day (300 to 600 mg/day in Japan), have shown marked overall clinical improvements in about 85% of patients. Symptomatic improvements in rehabilitation psychometric tests, neuromotor and speech deficits and other subjective symptoms have accompanied increased cerebral blood flow, particularly to ischaemic areas. Pentoxifylline would appear to be useful in most types of cerebrovascular disease including transient ischaemic attacks, sequelae of cerebral thrombosis and haemorrhage, and chronic ischaemic disorders. In patients with chronic cerebrovascular disease pentoxifylline 600 to 1200 mg/day conferred significant clinical benefit compared with placebo and in isolated studies proved to be superior to drugs such as co-dergocrine mesylate, adenosine and pyrithioxine.
Preliminary studies indicate that pentoxifylline may also prove useful in vaso-occlusive crises of sickle cell disease, some hearing disorders, disorders of eye circulation, high altitude sickness and asthenozoospermia. Pentoxifylline is usually well tolerated when administered as the conventional controlled release formulation, gastrointestinal symptoms (about 3%) being the most common complaint, although these and other adverse effects have not occurred to a significantly greater extent than with placebo.
Thus, pentoxifylline offers a well-tolerated and effective alternative to the treatment options available for patients with peripheral vascular disease. In cerebrovascular disease its relative place in therapy remains to be clarified with further comparative data.
Pharmacodynamic Studies
The primary pharmacodynamic effects of pentoxifylline are due to increased red blood cell deformability and to decreased blood viscosity. The increased deformability of erythrocytes has been clearly demonstrated in both in vitro and ex vivo studies involving blood from patients with peripheral vascular disease, cerebrovascular disease and a number of other conditions. The mechanism by which this is achieved has been shown to involve increased erythrocyte ATP and other cyclic nucleotide levels. Ex vivo studies have shown pentoxifylline to significantly reduce whole blood viscosity, and plasma viscosity by decreasing plasma fibrinogen concentrations. Pentoxifylline also strongly inhibits spontaneous and induced platelet aggregation in vitro and in vivo via inhibition of membrane-bound phosphodiesterase (leading to raised cAMP levels) and thromboxane synthesis, and increased prostacyclin (prostaglandin I2) synthesis. Platelet adhesion to vessel walls has been decreased with pentoxifylline in animals fed a high cholesterol diet, in a variety of tumour cell lines, and in patients with circulatory disorders. Experimental thrombus formation, either by stenosis or laser treatment, is also decreased with pentoxifylline.
Peripheral blood flow in the lower limbs and in the cerebral circulation is usually significantly increased after administration of pentoxifylline to patients. There is evidence to suggest that most benefit is obtained in ischaemic tissue and that it occurs without causing a ‘steal effect’. There are usually no effects on systemic blood pressure or heart rate and little evidence for a direct vasodilatory action with pentoxifylline after oral administration to patients. However, intravenous doses in animals have caused hypotension and decreased vascular tone in some studies.
Pentoxifylline produced increases in tissue oxygen tension in ischaemic lower limb muscles, in cerebral cortex, and in cerebrospinal fluid of patients with cerebrovascular disease. In animal studies, pentoxifylline increased cerebral oxygen consumption and glucose utilisation, increased cerebral cyclic nucleotide levels and decreased oedema formation. Pentoxifylline may produce favourable effects on electroencephalographic recordings in patients with cerebrovascular disease.
In most studies, pentoxifylline has had either beneficial or no effects on blood sugar and lipid metabolism in healthy subjects or patients with peripheral vascular complications of diabetes.
Pharmacokinetic Studies
Pentoxifylline is rapidly and extensively absorbed from the gastrointestinal tract both in animals and in humans. It is also rapidly metabolised systemically, with peak plasma concentrations of pentoxifylline (about 1100 µg/L) and one of its major metabolites (about 2000 µg/L) being reached at 1.05 and 1.8 hours, respectively, after administration of a 400mg capsule dose. Following administration of a 400mg sustained release dose (the commercially available dosage form), peak plasma concentrations of pentoxifylline and metabolite of about 300 and 343 µg/L were reached at 3.3 and 3.2 hours, respectively. Absolute bioavailability has been calculated as about 30 and 20% for the capsules and sustained release tablet formulations, respectively. However, recovery of metabolites in the urine accounted for almost the complete dose, suggesting that extensive enterohepatic recycling occurs. Pentoxifylline does not appear to significantly bind to plasma proteins and distribution was relatively uniform throughout body tissues. There seems to be no accumulation of drug with repeated doses.
Metabolism is primarily by reduction, to form metabolite 1 and by oxidation to form metabolites 4 and 5. Several other metabolites have been detected but exact metabolic pathways have yet to be determined. Rapid excretion into the urine occurs — primarily as metabolite 5 and, to a lesser extent, metabolite 4. Urinary recovery of these metabolites accounts for about 45 and 5% of the dose, respectively. Patients with renal insufficiency show decreased clearance of pentoxifylline. The elimination half-lives of pentoxifylline given as the capsule formulation (used in clinical trials) and conventional sustained release tablet formulations are about 0.8 and 3.4 hours, respectively.
Therapeutic Trials
The results of a large number of open and controlled studies show that pentoxifylline usually at a dosage of 600 to 1200 mg/day for at least 6 weeks is effective in improving symptoms of peripheral vascular disease in 60 to 100% of patients. In placebo-controlled studies, overall success rates have been significantly better with pentoxifylline (59 to 74%) than with placebo (5 to 29%). Subjective symptoms are improved in most patients — walking distance, rest pain, paraesthesia, cramps, ulcer healing, oedema, cyanosis — as are objective measurements such as reactive hyperaemia, and oscillographic, thermographic, plethysmographic, scintigraphic and ultrasound tests. Walking distance improvements have ranged markedly from study to study; open studies have usually shown increases approximating or exceeding 100%. Placebo-controlled clinical trials have generally confirmed the beneficial effect of pentoxifylline on walking distances. Studies on the effects of pentoxifylline on trophic leg ulcers have shown overall clearance or marked improvements in 61 to 87%, with one study showing clear superiority over placebo. In studies where patients were stratified according to initial severity of disease, pentoxifylline appeared to produce better results in more severely affected limbs, although between-study comparisons do not support these data.
In a limited number of comparative studies in patients with peripheral vascular disease, pentoxifylline has compared favourably (with respect to standard subjective and objective measures of disease activity) with most other agents. Pentoxifylline 1200 mg/day has produced significantly better results than nylidrin 9 mg/day and adenosine 7.2 mg/day, while a lower dose of 300 to 600 mg/day was as effective as pyridinolcarbamate 1500 mg/day and was superior to (recommended doses of) naftidrofuryl. However, in 2 studies comparing lower than recommended doses of pentoxifylline (800 mg/day and 300 mg/day) with buflomedil (600 mg/day and 450 mg/day), poor responses were seen to both drugs. Similarly, inconclusive results were seen in a comparison of pentoxifylline 1200 mg/day and flunarizine 15 mg/day.
Pentoxifylline has been studied in a few trials in diabetic patients with vascular complications, and has been shown to improve the symptoms of lower limb peripheral vascular disease. Other secondary complications, such as retinopathy may be improved, although further studies in this area are needed. Blood glucose concentrations and lipid metabolism in these patients are usually unaffected or improved. In one study in patients treated with pentoxifylline 1200 mg/day or dipyridamole 150 mg/day plus acetylsalicylic acid 1050 mg/day after vascular surgery, reocclusion of vessels occurred in 10% versus 20%, respectively.
In patients with cerebrovascular disorders, pentoxifylline has also shown evidence of therapeutic efficacy. However, few well controlled studies have been conducted, making it difficult to assess the relative efficacy of pentoxifylline in this therapeutic area. In one multicentre study 86% of nearly 13,000 patients showed clinical improvements during treatment with pentoxifylline 300 to 600 mg/day for 8 weeks. Significant improvements were documented for psychometric symptoms (disorientation, hypomnesia, loss of spontaneity, depression, insomnia — 64 to 78% of patients), speech disturbances (65%) and subjective symptoms such as tinnitus, cold extremities, headache, vertigo (76 to 87%). Stratification of these cerebrovascular disorder patients reveals improvements in high proportions of patients with transient ischaemic attacks (93%), cerebral infarction or thrombosis (85%) and in those with cerebral arteriosclerosis (89%).
In a comparative study of pentoxifylline 1200 mg/day and dipyridamole 150 mg/day plus acetylsalicylic acid 1050 mg/day in patients with transient ischaemic attacks, 12-month follow-up revealed incidences of new ischaemic attacks to be 10 to 13%, and 28 to 31%, respectively, and stroke incidences to be less than 5% with both treatments. Clinical improvements correlated with improved cerebral blood flow. In open studies in patients with acute cerebrovascular accidents pentoxifylline therapy has resulted in improvements in gross neuromotor and speech deficits, and overall rehabilitation. Comparative studies have demonstrated that pentoxifylline and xanthinol nicotinate both produce marked improvements in motor deficit in patients with cerebral thrombosis, with parenteral pentoxifylline also improving memory performance. A somewhat higher rate of rehabilitation was seen with parenteral pentoxifylline 400 mg/day than with a combination of hexobendine, ethamivan and etofylline in non-haemorrhagic stroke. Open studies in chronic cerebrovascular disorders have revealed improvements in about 60 to 90% of patients, and placebo-controlled studies have shown significant benefits with pentoxifylline, with improvements (haemorheological as well as clinical) in over 90% vs 15 to 20% of patients, respectively. Vertigo, headache and memory disturbances appeared to respond particularly well whereas visual disturbances were less responsive. Again, clinical improvements were accompanied by increased cerebral blood flow. Comparative studies in small numbers of patients with chronic cerebrovascular disorders have shown pentoxifylline up to 1200 mg/day to produce superior clinical improvements to treatment with codergocrine mesylate 6 mg/day (70% vs 10% of patients), and adenosine 7.2 mg/day (100% vs 37.5% of patients). Comparison of pentoxifylline 1200 mg/day, dipyridamole 300 mg/day or a combination of the two resulted in clinical improvements in 67%, 67% and 83% of patients, respectively. However, in a similar study comparing pentoxifylline 1200 mg/day with placebo, piracetam 4800 mg/day or a combination of pentoxifylline with piracetam, significant clinical improvements were observed only with the combination therapy.
Pentoxifylline has also shown some potential for use in a number of other disorders including the vaso-occlusive crises of sickle cell disease, high altitude sickness, asthenozoospermia (but not oligospermia), acute and chronic hearing disorders, and disorders of eye circulation. However, the encouraging preliminary results in these areas need further confirmation.
Side Effects
In placebo-controlled studies in patients with peripheral vascular disorders, the conventional sustained release formulation of pentoxifylline has been very well tolerated by most patients. Gastrointestinal symptoms (about 3%) are the most common complaint, although these and other side effects have not occurred to a significantly greater extent than with placebo. Discontinuation due to adverse effects occurred in 3.1 and 0% of patients receiving pentoxifylline and placebo, respectively. In patients with cerebrovascular disease, gastrointestinal disturbances were again most common, with side effects of other organ systems occurring in less than 0.25% of patients treated with pentoxifylline 300 to 600 mg/day.
Dosage and Administration
The usual adult oral dosage of pentoxifylline in the treatment of peripheral vascular disease is 1200mg daily in 3 divided doses with meals. Therapy should be maintained for at least 8 weeks. In cerebrovascular diseases the most often used dosage in clinical trials has been 300 to 600mg daily, although the currently recommended dosage is 600 to 1200mg daily.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams HL, McNeil BJ. Medical complications of computed tomography (part 1). New England Journal of Medicine 298: 255–261, 1978a
Abrams HL, McNeil BJ. Medical complications of computed tomography (part 2). New England Journal of Medicine 298: 310–318, 1978b
Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of doubleblind study versus vasodilator nylidrin. American Heart Journal 103: 864–869, 1982
Acheson J, Danta G, Hutchinson EC. Platelet adhesiveness in patients with cerebral vascular disease. Atherosclerosis 15: 123–127, 1972
Adisasmito NA, Wiradinata BW. The clinical effect of pentoxifylline (Trental) in the treatment of geriatric patients. Singapore Medical Journal 20(Suppl. 1): 20–25, 1979
Ambrus JL, Ambrus CM, Taheri SA, Gastpar H, Reddington MM, et al. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches. Angiology 35: 418–426, 1984a
Ambrus CM, Ambrus JL, Gastpar H, Sharma SD, Suhow B, et al. The role of fibrinolysis in the therapy of peripheral vascular disease. Angiology 35: 436–442, 1984b
Ambrus JL, Ambrus CM, Gastpar H. Studies on platelet aggregation and platelet interaction with tumor cells. In de Gaetano and Garattini (Eds) Platelets: a multidisciplinary approach, pp. 467–480, Raven Press, New York, 1978
Ambrus JL, Ambrus CM, Gastpar H. Studies on platelet aggregation with pentoxifylline: effect in neoplastic disorders and other new indications. Journal of Medicine 10: 339–345, 1979a
Ambrus JL, Ambrus CM, Gastpar H. New clinical indications for Trental. Singapore Medical Journal 20(Suppl. 1): 1–5, 1979b
Andreeva NJ, Gegutschadze MD, Gelashwili AP, Kipiani VA, Natadze TG, et al. The effect of pentoxifylline on regional vascular systems. Current Medical Research and Opinion 6(Suppl. 4): 57–59, 1979
Angelides NS. Continuous infusion treatment with pentoxifylline in patients with severe peripheral vascular occlusive disease. Angiology 37: 555–564, 1986
Angelkort B. Influence of pentoxifylline (Trental 400) on micro-circulation, post-stenotic blood pressure and walking capacity in patients with chronic occlusive arterial disease. IRCS Medical Science 5: 370, 1977
Angelkort B. Thrombozytenfunktion, plasmatische Blutgerinnung und Fibrinolyse bei chronisch arterieller Verschluss Krankheit. Medizinische Welt 30: 1239–1248, 1979
Angelkort B. Coagulation phenomena and blood fluidity in peripheral occlusive arterial disease. Study with pentoxifylline. In Manrique & Müller (Eds) Disorders of blood flow; new therapeutic aspects, pp. 68–79, Excerpta Medica, Amsterdam, 1981
Angelkort B, Bauerdick H. Zum Verhalten des Herzrhythmus bei digitalisierten Patienten mit zusätzlicher Pentoxifyllin-Medikation. Therapiewoche 32: 5369–5371, 1982
Angelkort B, Doppelfeld E. The treatment of chronic arterial occlusion: a clinical study with a new formulation of pentoxifylline (Trental 400). Pharmatherapeutica 3(Suppl. 1): 18–29, 1983
Angelkort B, Kiesewetter H, Pimay M. Hemodilution and pentoxifylline medication — two possible therapeutic measures in chronic occlusive arteriopathies. Proceedings of the German-Japanese Congress Angiology pp. 422–424, 1981
Angelkort B, Maurin N, Boateng K. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Current Medical Research and Opinion 6: 255–258, 1979
Angelkort B, Pimay D, Kiesewetter H, Maurin N. Hemodilution and pentoxifylline effects on muscle blood flow and blood fluidity in chronic arterial occlusive disease. Vascular Medicine 1: 150–158, 1983
Angelkort B, Spürk P, Habbaba A, Mähder M. Blood flow properties and walking performance in chronic arterial occlusive disease. Angiology 36: 285–292, 1985
Aparicio NJ, Schwarzstein L, de Turner EA. Pentoxifylline (BL191) by oral administration in the treatment of asthenozoospermia. Andrologia 12: 228–231, 1980
Aste J, Avila Paz A, Bacarra H, Brinon F. Trental forte en al tratamiento de pacientes con insuficiencia cerebrovascular. Semana Medica 157: 827–833, 1980
Atarashi J, Shoda T, Araki G, Itahara K, Ohyama K, Otomo E, et al. Clinical efficacy of pentoxifylline (BL191) and pyrithioxine hydrochloride in treatment of cerebrovascular disorders. Clinical Evaluation 4: 213–230, 1976
Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Pharmacotherapy 4: 297–307, 1984
Barnes AJ, Locke P, Scudder PR, Dormandy TL, Dormandy JA, Slack J. Is hyperviscosity a treatable component of diabetic microcirculatory disease? Lancet 2: 789–791, 1977
Baskerville VW. Clinical trial with pentoxifylline in geriatric patients with cerebral circulatory insufficiency. Revista Brasiliera de Clinicà e Terapeutica 9: 41–50, 1980
Baumann JC. Doppler ultrasonic blood pressure measurements in limbs with occlusive arterial disease and in normal lower extremities under treatment with pentoxifylline. IRCS Medical Science 4: 93, 1976
Baumann JC. A clinical pharmacological comparison of the two vasoactive compounds, pentoxifylline and xanthinol nicotinate. Pharmatherapeutica 2(Suppl. 1): 58–65, 1978
Baumann JC. New prospects for the conservative management of peripheral arterial disease: clinical investigations with pentoxifylline (Trental 400). Pharmatherapeutica 3(Suppl. 1): 30–41, 1983
Beermann B, Ings R, Månsby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clinical Pharmacology and Therapeutics 37: 25–28, 1985
Beitz D. Vaskuläre Erkrankungen des Augenhintergrundes. Therapiewoche 33: 4672–4685, 1983
Betow Ch, Reppel PD. Therapeutische Erfahrungen bei Meniere und Hörsturz. Berliner Arzteblatt 90: 937–938, 1977
Beyreder J. Use of pentoxifylline in the treatment of acute cerebrovascular insufficiency. European Neurology 22(Suppl. V): 116–123, 1983
Biamino G. Influence of a single IV dose of pentoxifylline on central haemodynamics in patients with ischemic heart disease. IRCS Medical Science 14: 82–83, 1986
Biddle W, Ambrus CM, Gastpar H, Ambrus JL. Antineoplastic effect of the xanthine derivative, Trental. Journal of Medicine 15: 355–366, 1984
Bieber C. Neuere Aspekte der Antikoagulationsbehandlung mit Heparin bei Okklusionen der Vena Centralis Retinae und ihren. Ästen. Ph.D Thesis, University of Aachen, 1983
Blagosklonnaya YV, Marmedov R, Kozlov VV, Emanuel VL, Kudryashov MI. Effect of Trental on some renal function parameters in diabetes mellitus patients. Problemy Endokrinologii (Moskva) 28: 3–8, 1982
Bluhm RE, Cohen MM. Protection by pentoxifylline against ischemic deterioration of cerebral metabolism. Neurology 28: 378, 1978
Bluhm RE, Molnar J, Cohen MM. The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain. Clinical Neuropharmacology 8: 280–285, 1985
Bluhm RE, Cohen MM. Protection by pentoxifylline against ischemic deterioration of cerebral metabolism. Neurology 28: 378, 1978
Boisseau MR, Lorient MF, Bricaud H. Red cell deformability and risk factors in one hundred patients with cerebrovascular thrombosis. Presented at 7th International Congress on Thrombosis and Haemostasis, London, 1979
Boksay J, Bollmann V. The effect of 3,7-dimethyl-1-(5-oxohexyl)-xanthin on the β-adrenergic receptors and on the activity of isoprenaline. Archives of Internal Pharmacodynamics and Therapeutics 194: 174–180, 1971
Bollinger A, Frei C. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharma-therapeutica 1: 557–562, 1977
Bossong W. Klinische Erfahrungen mit dem Vasotherapeutikum Trental in der Dermatologie. Zeitschrift für Hautkrankheiten 46: 711–724, 1972
Braasch D. Red cell deformability and capillary blood flow. Physiological Reviews 51: 679–697, 1979
Bramante MA, Draghi ME, Baravia L. Clinical evaluation about pentoxifylline treatment in retinal branch vein occlusions. Annals di Optalmologia 109: 49–60, 1983
Brancato R, Menchini U, Michelone C. Evaluation of the action of pentoxifylline on the conjunctival microcirculation in diabetics. Pharmatherapeutica 3(Suppl. 1): 42–45, 1983
Brevetti G, Abate S, Lavecchia G, Ferulano G, Paudice G, Acunzo R. La pentossifillina nel trattamento delle arteriopatie obliteranti al secondo stadio. Progresso Medico (Rome) 35: 363–368, 1979
Bryce TA, Burrow JL, Jolley KW. Determination of 1-(3′-carboxypropyl)-3,7-dimethylxanthine and 1-(4′-carboxybutyl)-3,7,-dimethylxanthine, two major metabolites of oxpentifylline, in urine by high-performance liquid chromatography. Journal of Chromatography 344: 397–402, 1985
Buchanan N, Moodley GP. The effect of pentoxifylline on human erythrocyte adenosine triphosphate. IRCS Medical Science 5: 43, 1977
Buckert D, Harwart D. Trials of 3,7-dimethyl-1-(5-oxohexyl) xanthine (BL191) in double-blind tests. Farmaco 31: 264–274, 1976
Bunyaratavej S. Clinical experience of pentoxifylline in the microsurgery of intracranial aneurysms. Singapore Medical Journal 20(Suppl. 1): 26–28, 1979
Calamera JC, Nicholson R, Brugo S, Vilar O. Effects of methyl-xanthines upon the spermatozoa adenosinetriphosphate (ATP) concentration in normal semen. Andrologia 16: 358–361, 1984
Cardinali DP. Effect of pentoxifylline and aminophylline on biogenic amine metabolism of the rat brain. European Journal of Pharmacology 47: 239–243, 1978
Chien S. Principles and techniques for assessing erythrocyte deformability. Blood Cells 3: 71–99, 1977
Christ O, Gleixner K, Kellner RM, Müller R, Rupp W. Pharmakokinetische Untersuchungen nach oraler Verabreichung von 3,7-dimethyl-1-(5-oxo-hexyl)-xanthin —14C (BL 191-14C) an Ratten, Hunde und Menschen. Arzneimittel-Forschung 22: 1933–1937, 1972
Clyne CAC. Can drug therapy alter the natural course of peripheral vascular disease. Proceedings of the Royal Society of Medicine 7(Suppl. 8): 29–34, 1977
Cohen MM, Harrison W, Gray R, Becker R. The effect of pentoxifylline on cerebral ischemia and amino acid incorporation into gerbil brain. Proceedings of the Annual Meeting of the American Neurology Association, St Louis, 1979
Dannhof S. Untersuchungen über die Beeinflussung des muskulären Sauerstoffdruckes bei Patienten mit chronischen arteriellen Verschlusserkrankungen durch Pentoxifyllin. Doctoral Thesis, Frankfurt University, 1978
Deguchi K, Ito T, Shima H, Uno N, Nakamori I, Ueno H, et al. Clinical use of pentoxifylline — concerning blood viscosity and platelet function. Mie Medicine 21: 375–380, 1977
Dembowski U, Marx-Heep I, Adams HJ. Angioneuropathies, angiopathies and other circulatory disorders. Treatment of outpatients. Zeitschrift fur Allgemeine Medizin 55: 1583–1586, 1979
De Medeiros A, Silveira PRM. The use of pentoxifylline in the treatment of intermittent claudication. Revista Brasileira de Clinica e Terapeutica 13: 339–342, 1984
De Oliveira RSP, de Miranda AAV. Estudo eletroencefalografico e psicologico com BL-191 em pacientes geronto-psiquiatrico. Revista Brasiliera de Medicina 34: 85–93, 1977
Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorheologic effect for the treatment of intermittent claudication. Journal of Clinical Pharmacology 25: 8–26, 1985
De Turner EA, Aparicio NJ, Turner D, Schwarzstein L. Effect of two phosphodiesterase inhibitors, cyclic adenosine 3’5’ monophosphate and a β-blocking agent on human sperm motility. Fertility and Sterility 29: 328–331, 1978
Deutschinoff A, Grozdinsky L. Rheological and anticoagulant therapy of patients with chronic occlusive arterial disease. Angiology 37: 396, 1986
Dintenfass L. Effect of 3,7-dimethyl-1-(5-oxohexyl)-xantin (Trental, BL 191) on the blood viscosity factors in vitro. Pharmatherapeutica 1: 290–299, 1976
Di Perri T, Carandente O, Vittoria A, Guerrini M, Messa GL. Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 35: 427–435, 1984
Dodds AJ, Boyd M, Allen J, et al. Change in red cell deformability and other haemorheological variables after myocardial infarction. British Heart Journal 44: 508, 1980a
Dodds AJ, Matthews PN, Bailey MJ, Flute PT, Dormandy JA. Changes in red cell deformability following surgery. Thrombosis Research 18: 561–565, 1980b
Dohrmann RE, Kessel ME, Heller RF. Therapeutische Ergebnisse beim akuten Myokardinfarct unter Anwendung hochdosierte Steroidgaben und fluidiläts beeinflussender Pharmaka. Therapiewoche 31: 8301–8307, 1981
Dominguez D. Vascular dementia and neuropsychological disorders of the ageing brain. In Gotoh and Lehrer (Eds) Clinical haemorheology: a new approach to cerebrovascular disease, pp. 19–23, Royal Society of Medicine Services, London, 1986
Dominguez D, de Cayaffa CL, Gomensoro J, Aparicio NJ. Modification of psychometric, practical and intellectual parameters in patients with diffuse cerebrovascular insufficiency during prolonged treatment with pentoxifylline: a double-blind, placebo controlled trial. Pharmatherapeutica 1: 498–506, 1977
Don RG. Experiences with Trental in stroke rehabilitation. Singapore Medical Journal 20(Suppl. 1): 13–19, 1979
Donaldson DR, Hall TJ, Kester RC, Ramsden CW, Wiggins PA. Does oxpentifylline (Trental) have a place in the treatment of intermittent claudication? Current Medical Research and Opinion 9: 35–40, 1984
Dormandy JA. What is viscosity? Viscositas 1: 1–4, 1979a
Dormandy JA. Clinical importance of blood viscosity. Viscositas 1: 5–9, 1979b
Dormandy JA. Reduced red cell deformability. In Davis and Marcel (Eds) Symposium on Recent Developments in Microcirculation Research, pp. 45–53, Excerpta Medica, Amsterdam, 1981
Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication. British Medical Journal 4: 576–581, 1973a
Dormandy JA, Hoare E, Khattab AH, Arrowsmith DE, Dormandy TL. Prognostic significance of Theological and biochemical findings in patients with intermittent claudication. British Medical Journal 4: 581–583, 1973b
Dvorkin SB, Cemookij GP. Conservative treatment of trophic skin ulcers with Trental. Vestnik Dermatologii i Venerologii 4: 51–52, 1985
Editorial. Alzheimer’s disease. British Medical Journal 281: 1374–1375, 1980
Editorial. Red cell deformability. Lancet 2: 1348–1349, 1978
Ehrly AM. Beeinflussung der Verformbarkeit der Erythrocyten durch Pentoxifyllin. Medizinische Welt 26: 2300–2301, 1975a
Ehrly AM. The effect of pentoxifylline on the flow properties of hyperosmolar blood. IRCS Medical Science 3: 465, 1975b
Ehrly AM. The effect of pentoxifylline on the flow properties of human blood. Current Medical Research and Opinion 5: 608–613, 1978
Ehrly AM. New aspects of pathophysiology and therapy of chronic arterial diseases. In Manrique & Müller (Eds) Disorders of blood flow: new therapeutic aspects, pp. 23–28, Excerpta Medica, Amsterdam, 1981
Ehrly AM. Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. IRCS Medical Science 10: 401–402, 1982
Ehrly AM. Measurements of oxygen tension in muscle. In Spittell (Ed.) Pharmacological approach to the treatment of limb ischemia, pp. 65–72, College of Physicians of Philadelphia, Philadelphia, 1983
Ehrly AM. The effect of pentoxifylline on the muscle tissue oxygen pressure of claudicants after pedoergometric exercise. Angiology 37: 398, 1986
Ehrly AM, Rossbach P. The detection of changes in erythrocyte shape by a filtration method using 8μm filters. In Gerlach (Eid.) Erythrocytes, thrombocytes, leucocytes, pp. 52–53, Thieme Verlan, Berlin, 1979
Ehrly AM, Schroeder W, Dannhof St. The effect of pentoxifylline on the oxygen pressure of ischaemic muscle tissue in patients with chronic arterial occlusions. IRCS Medical Science 5: 411, 1977
Eisenberg S. Blood viscosity and fibrinogen concentration following cerebral infarction. Circulation 24(Suppl. 2): 10–14, 1966
Ekestrom S, Liljeqvist L, Nordhus O. Central haemodynamics and coronary blood flow after administration of pentoxifylline to patients with coronary artery disease: a preoperative study. In Rietbrock et al. (Eds) Theophylline and other methylxanthines, pp. 233–243, Vieweg, Wiesbaden, West Germany, 1981
Eninja GJ, Tegere DA, Robuljc VK, Majore JK. Hinweise zur Anwendung von Trental bei beginnender Symptomatik einer insuffizienten Hirndurchblutung. Zhumal Neuropatologii i Psikhiatrii Imeni ss Korsakova 86: 50–52, 1986
Feine-Haake G. Zur Objektivierung der therapeutischen Wirksamkeit von Trental 400. Fortschritte der Medizin 95: 48–51, 1977
Feine-Haake G. Assessment of the therapeutic efficacy of pentoxifylline (Trental 400): a double-blind trial in geriatric patients with vascular disorders. Pharmatherapeutica 3(Suppl. 1); 46–51, 1983
Fellner R, Simon A. Untersuchungen ueber die durchblutungsverbessemde Wirkung von BL 191 auf die Chorioidea des menschlichen Auges. Klinische Monatsblätter fur Augenheilkunde 161: 439–444, 1972
Fellner R, Simon A. Klinische Erfahrungen mit einem neuen Vasotherapeutikum bei Erkrankungen des Augenhintergrundes. Klinische Monatsblätter für Augenheilkunde 162: 811, 1973
Ferraresi I, Bossini F, Torta D, Frigerio R, Bemasconi C, et al. In vitro effects of pentoxifylline on hemoglobin affinity for oxygen and electrolytic equilibrium of human blood. Ricerca in Clinica e in Laboratorio 13: 459–465, 1983
Figini J, Bonavia L, Bliu M, Bertoni G. Studio comparato sull azione della pentoxifillina nelle occlusioni venose retiniche. Ricerca in Clinica e in Laboratorio 15(Suppl. 1): 567–570, 1985
Fjodorov NA, Termiltschenko GV, Vinnizkij LI, Malychina LS, Krasjukova LI, et al. Clinical and experimental investigations into the role of 3’, 5’ cyclic guanosine monophosphate (cGMP) in the mechanism of action of pentoxifylline. Pharmatherapeutica 2(Suppl. 1): 17–20, 1978
Flamm P, Lehrach F, Weiser HG. Durchblutungsstörungen des Netzhaut-Aderhaut-Bereichs und ihre Behandlungsmöglichkeiten mit Pentoxifylline. Therapiewoche 28: 9911–9918, 1978
Foley KM. Neurologie diagnostic procedures. In Beeson et al. (Eds) Textbook of medicine, pp. 746–750, W.B. Saunders Company, Philadelphia, 1979
Forteleoni G, Pacitti C, Mulas G, Careddu F, Antona C, et al. La nostra esperienza nel trattamento delle ulcere malleolari nella talessemia. Terapia 74: 1173–1178, 1983
Fujimoto K, Yoshida S, Moriyama Y, Sakaguichi T. Absorption, distribution, excretion and metabolism of 1-(5-oxohexyl)theobromine (BL 191) in rats. Chemistry and Pharmacy Bulletin 21: 1137–1145, 1976
Fukuda I, Yoshida T, Yoritsune H, Kiso T, Konishi S, et al. Studies on the hemorheological factors in ischemic heart disease and cerebrovascular disorders. Bulletin of the Osaka Medical School 24: 83–91, 1978
Gabaschwili VM, Kobaladze SG, Schakaraschwili RR, Virsaladze MD, Petriaschwili SP, et al. The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. Current Medical Research and Opinion 6(Suppl. 4): 25–29, 1979
Gaillard S, Schooneman F, Voisin Ph, Pointel JP, Rousselle D, et al. Effets comparés sur la filtrabilité in vivo chez l’homme de deux formes galéniques de la pentoxifylline. Annales Médicales de Nancy 18: 1099–1102, 1979
Gallasch G. Ergebnisse Indikationsstellung medikamentöser Therapie bei arteriellen und venösen Gefässverschlüssen der Retina durch Erythrosklerose. Fortschritte der Ophthalmologie 82: 102–104, 1985
Gallenkämper W, Rücker W, Schrör K. Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia. British Journal of Pharmacology 81: 575–581, 1984
Gallus AS, Morley AA, Gleadow F, Wenzel A, Dupont P, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Australian and New Zealand Journal of Medicine 15: 402–409, 1985
Ganser V, Boksay I. Effect of pentoxifylline on cerebral edema in cats. Neurology 24: 487–493, 1974
Garcia PM. Clinical investigation with a blood viscosity reducing agent in patients with peripheral vascular diseases. In Manrique & Müller (Eds) Disorders of blood flow: new therapeutic aspects, pp. 93–94, Excerpta Medica, Amsterdam, 1981
Gamier F, George C, Marcel GA, et al. Etude multicentrique Torental 400 — arterite facteurs de risque vasculaire analyse intermediaire. Actualites Angiologie 7: 39–46, 1982
Gastpar H. The inhibition of cancer cell stickiness by the methyl-xanthine derivation pentoxifylline (BL 191). In Goossens (Ed.) Thrombosis Research, pp. 277–289, Pergamon Press, 1974
Gastpar H. Platelet-cancer cell interaction in metastasis formation: a possible therapeutic approach to metastasis prophylaxis. Journal of Medicine 8: 103–114, 1977
Gastpar H. New aspects of the pathogenesis of atherosclerosis: possible approaches to prevention and treatment. Current Medical Research and Opinion 7: 142–155, 1981
Gastpar H, Ambrus JL, Ambrus CM. Studies on platelet aggregation in vivo VII: effect of pentoxifylline on circulating tumour cells. Journal of Medicine 9: 265–268, 1978
Gastpar H, Ambrus JL, Ambrus CM, Spavento P, Weber FJ, Thurber LE. Study of platelet aggregation in vivo III. Effect of pentoxifylline. Journal of Medicine 8: 191–197, 1977
Gincherman EZ, Titova SI, Masoveckij AG. Use of antiaggregating and haemostatic drugs in the treatment of diabetic retinopathy. Problemy Endokrinologii (Moskva) 28: 17–22, 1982
Giraud F, Claret M. Lack of effect of pentoxifylline on membrane lipid order and ion transports in human red cells. Scandinavian Journal of Clinical and Laboratory Investigations 41(Suppl. 156): 283–284, 1981
Goldberg J, Diesk A. Successful treatment of Raynauds phenomenon with pentoxifylline. Arthritis and Rheumatism 29: 1055–1056, 1986
Goltseva SV. Comparative assessment of efficacy of various methods for treatment of diabetic retinopathies. Optalmologii Zhurnal 38: 36–38, 1983
Gorbatschova FE, Turaschwili GA, Kvassov VT, Milovanova NM, Tschistjakova MA, et al. The circulatory and clinical effects of pentoxifylline. Pharmatherapeutica 2(Suppl. I): 100–104, 1978
Gordon S, Witul M, Cohen H, Sciandra J, Williams P, Gastpar H, et al. Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis. Journal of Medicine 10: 435–443, 1980
Grigoleit HG. Erythrozytenverformbarkeit Physiologie und Methodologie. Labormedizin 2(Sonderheft): 411–413, 1979
Grigoleit HG, Jacobi G. Microrheological effects of the vasoactive compound 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (Pentoxifylline, BL 191). Vasa 6: 274–278, 1977
Grigoleit HG, Lehrach F. Blutviskosität und Diabetes mellitus. Medizinische Monatsschrift 27: 353–356, 1973
Grigoleit HG, Porsche E, Stefanovich V, Jacobi G, Lahham A. The effect of pentoxifylline on red cell flexibility in healthy subjects after administration of Trental 400. Pharmatherapeutica 1: 241–247, 1976
Guerrini M, Pecchi S, Rossi C, Cappelli R, Pieragalli D, Acciavatti A. Effect of pentoxifylline on blood hyperviscosity and peripheral haemodynamics in patients with peripheral obliterating arterial disease. Pharmatherapeutica 3(Suppl. 1): 52–66, 1983
Guillot C, Marcel GA, Stoltz J. Influence of pentoxifylline on erythrocyte filtrability and microrheology. Proceedings of the 3rd International Congress of Biorheology, La Jolla, 1978
Habu K, Hara Y, Mikami Y, Honda M. Studies on the erythrocyte osmotic fragility of patients suffering from vibration disease tested with the coil planet centrifuge. Journal of the Japan Accident Medical Association 26: 703–715, 1978
Hadjiev D. Microcirculation in the transient ischaemic attacks. Proceeding of Conference on Blood Rheology and Microcirculation, Capri, Italy, 1980
Hartmann A. Effect of pentoxifylline on regional cerebral blood flow in patients with cerebrovascular disease. Proceedings of the 28th International Congress of Physiological Sciences, Tübingen, West Germany, 1980
Hartmann A. Cerebral blood flow in patients with cerebrovascular disorders — study with pentoxifylline. La Ricerca in Clinica e in Laboratorio II(Suppl. 1): 243–246, 1981
Hartmann A. Effect of pentoxifylline on regional cerebral blood flow in patients with cerebral vascular disorders. European Neurology 22(Suppl. 1): 108–115, 1983a
Hartmann A. Prolonged disturbances of cerebral blood flow in patients with transient ischemic attacks. Egyptian Journal of Neurology, Psychiatry and Neurosurgery 22: 189–200, 1983b
Hartmann A. Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and co-dergocrine mesylate in patients with chronic cerebrovascular disease. Current Medical Research and Opinion 9: 475–479, 1985
Hartmann A. Haemorheological treatment of acute cerebral ischaemia. In Gotoh & Lechner (Eds) Clinical haemorheology — a new approach to cerebrovascular disease, pp. 65–73, Royal Society of Medicine Services, London, 1986
Hartmann A, Alberti E, Lange D. Effect of pentoxifylline on regional CBF and CBV in dementia. Acta Neurologica Scandinavica 60(Suppl. 72): 624–625, 1979
Hartmann JF, Becker RA, Cohen MM. Effects of pentoxifylline on cerebral ultrastructure of normal and ischemic gerbils. Neurology 27: 77–84, 1977
Härtwig J, Dietel G, Drewes U. Therapeutische Möglichkeiten zur Vermeidung von stiellappennekrosen. Medizinische Welt 27: 124–127, 1976
Harwart D. The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline (Trental 400). Current Medical Research and Opinion 6: 73–84, 1979
Hatano R, Mishima Y, Iwai T, Ohashi S, Orii M, et al. Clinical effectiveness of Trental (pentoxifylline) in the treatment of chronic arterial occlusive diseases. Junkanki-ka 13: 168–180, 1983
Hauss T, Schönleben K, Spiegel U, Kessler M. Measurements of local oxygen pressure in skeletal muscle of patients suffering from disturbances of arterial circulation. In Silver et al. (Eds) Oxygen transport to tissue, pp. 419–422, Plenum Publishing Corporation, London, 1978
Hayashi S, Ozawa H. Studies on 3,7-Dimethyl-1-(5-oxo-hexyl)-xanthine (BL191). I. Cyclic 3,’5’-nucleotide phosphodiesterase (PDE) and the inhibitory effect of BL191 on PDE in rat brain and heart. Chemical and Pharmaceutical Bulletin 22: 587–593, 1974
Heidrich H, Ott M. Vasodilatantien und Blutviskosität. Herz-Kreislauf 6: 542–546, 1974
Heidrich H, Paeprer M, Barekow D, Schartl M. The effect of pentoxifylline on central and peripheral hemodynamics — an experimental clinical study. Zeitschrift für Kardiologie 65: 385–391, 1976b
Heidrich H, Schirop T. Blood glucose and serum insulin levels following acute and chronic pentoxifylline administration. Acta Diabetologica 17: 15–21, 1980
Heidrich H, Schlichting K, Ott M. Changes in blood viscosity due to pentoxifylline IRCS Medical Science 4: 368, 1976a
Heilmann E, Laage HM, Zimmermann E, Dorsk H. Therapeutic influence on flexibility of erythrocytes in sickle cell anemia. Innere Medizin 9: 277–280, 1982a
Heilmann E, Zimmermann B, Gruss P. Effect of pentoxifylline on hypercoagulability in patients with polycythemia vera. IRCS Medical Science 10: 594–595, 1982b
Heinen A, Brunner R, Hossmann V, Konen W, Roll K, et al. Different types of therapy having haemorheological effects in patients with impairment of blood supply to the retina — randomised double blind study. Clinical Hemorheology 6: 61–79, 1986
Heinsius E, Flamm P. Ophthalmologische Erfahrungen mit dem neuen Xanthinkörper BL 191. Medizinische Klinik 68: 1540, 1973
Heisig A, Stolterfoht CA. Infrarotthermographie zum Nachweis der Gefässwirksamkeit eines neuen Xanthinderivates. Fortschritte der Medizin 89: 735–739, 1971
Heite HJ, Koschnike J. Der Einfluss von Pentoxifyllin auf das Spermiogramm. Eine Klinische Studie an Patienten mit herabgesetster Fertilität. Aktualne Dermatologii 5: 247–254, 1979
Hennig FC. Die Bestimmung von ATP in Erythrocyten durch chemische Lumineszenz. Doctor Thesis Medical Faculty Siene, Italy, 1984
Hensel A. Effect of pentoxifylline on adenine nucleotide content of human erythrocytes. Proceedings of the 16th International Congress of Hematology pp. 2/31, Kyoto, 1976
Herger R. Erfahrungen mit dem neuen Vasotherapeutikum Trental in der dermatologischen Fachpraxis. Fortschritte der Medizin 24: 865–872, 1972
Herger R. Zum Stellenwert der Mikrozirkulation in der Behandlung des Ulcus cruris. Therapiewoche 36: 3818–3828, 1986
Hermel B, Forminska M, Jassiak B, et al. Treatment of retinal vein thrombosis. Klinika Oczna 83: 395–396, 1981
Hermel B, Szymanski F, Adamus F. Trials of Trental in treatment of diabetic angiopathy. Klinika Oczma 83: 255–256, 1981
Herskovits E, Famulari A, Tamaroff L, Gonzales AH, Vazquez A, et al. Preventive treatment of cerebral transient ischemia: comparative randomised trial of pentoxifylline vs conventional aggregants. European Neurology 24: 73–81, 1985
Herskovits E, Famulari K, Tamaroff L, Smud R, Vazquez A, et al. Randomised trial of pentoxifylline versus acetylsalicylic acid + dipyridamole in preventing transient ischemic attacks. Lancet 1: 966–967, 1981
Herskovits E, Vazquez A, Famulari A, Tamaroff L, Fraiman H, Gonzales AM, et al. A randomised clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks. A one-year follow-up. Proceedings of Conference on Blood Rheology and Microcirculation, Capri, Italy, 1980
Hess Von H, Franke I, Tauch M. Medikamentöse Verbesserung der Fliesseigenschaften des Blutes. Fortschritte der Medizin 91: 743–748, 1973
Hinze HJ. Analysis of 3,7-dimethyl-l-(5-oxo-hexyl)-xanthine. Part 1: The spectroscopy of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine. Arzneimittel-Forschung 21: 1456–1459, 1971a
Hinze HJ. Analysis of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine. Part 2: Chromatography and quantitative estimation of BL 191. Arzneimittel-Forschung 21: 2045, 1971b
Hinze HJ. The pharmacokinetics of 3,7-dimethyl-l-(5-oxo-hexyl)-xanthine (BL191) in man. Arzneimittel-Forschung 22: 1492–1495, 1972
Hinze HJ, Bedessem G, Söder A. Structure of the excretion products of 3,7-dimethyl-l-(5-oxo-hexyl)-xanthine (BL 191) in man. Arzneimittel-Forschung 22: 1144–1151, 1972
Hinze HJ, Grigoleit HG, Rethy B. Bioavailability and pharmacokinetics of pentoxifylline from Trental 400 in man. Pharmatherapeutica 1: 160–171, 1976
Hirokawa M, Iwamoto T, Sato K, Matsushita K, Asakura S. Clinical application of pentoxifylline to subfertile men, with regard to the statistical evaluation of the therapeutic effect of semen parameters. Japanese Journal of Fertility and Sterility 26: 57–63, 1981
Honegger H. Untersuchung der zentralen Durchblutung mit Hilfe der Ophthalmodynamographie. Folia Angiologia 21: 207–213, 1973
Hörmann K, Fritz W, Lemke Th. Viskosität des Blutes unter Hörsturztherapie. Archives Oto-Rhino-Laryngology 227: 383–385, 1980
Horowitz I. Resultats d’une etude multicentrique randomisée en double aveugle: pentoxifylline contre placebo prolongee sur 6 mois dans les arteriopathies des membres inferieurs. Actvalites Angiologie 7: 31–34, 1982
Huppertz M. Klinische Erfahrungen mit einem neuen Xanthinderivat (BL191) bei der Behandlung akuter Hörminderungen oder Ertaubungen. Therapiewoche 23: 5008–5017, 1973
Iijima M. Changes in gas content of blood and CSF in CVD patients, especially those at the chronic stage of CVD. Proceeding of the 3rd General Meeting of the Japanese Society of Stroke, Report No. 252, Akita, 1978
Ingerslev J, Mouriken G, Stenbjerg S. Pentoxifylline does not interfere with stable coumarin anticoagulant therapy: a clinical study. Pharmatherapeutica 4: 595–600, 1986
Itoh T, Satoh T. Influence of pentoxifylline (Trental) on platelet aggregation and serum lipids in patients with obstructive cerebrovascular disorders. Pharmatherapeutica 2: 159–164, 1979
Iwafune Y, Yoshimoto H. Clinical use of pentoxifylline in haemorrhagic disorders of the retina. Pharmatherapeutica 2: 429–438, 1980
James DR, Holland BM, Hughes MR, Jones JG, Wardrop CAJ. Oxpentifylline: effects on red cell deformability and oxygen availability from the blood in intermittent claudication. Clinical Hemorheology 4: 525–531, 1984
Janaki S. Pentoxifylline in strokes: a clinical study. Journal of International Medical Research 8: 56–62, 1980
Jarrett PEM, Moreland M, Browse NL. The effect of oxpentifylline on fibrinolytic activity and plasma fibrinogen levels. Current Medical Research and Opinion 4: 492–495, 1977
Johnsson R. Effect of pentoxifylline on red cell flexibility and cation transport in healthy subjects and patients with hereditary spherocytosis. Scandinavian Journal of Haematology 23: 81–87, 1979
Johnsson R, Harjola PT, Siltanen P. Effect of pentoxifylline on red cell flexibility in arteriosclerotic patients with heart valve prosthesis. Scandinavian Journal of Laboratory Investigations 41(Suppl. 156): 297–300, 1981
Jovanović UJ. Polygraphische Registrierungen nach parenteraler Applikation von 3,7-dimethyl-l-(5-oxo-hexyl)-xanthin (BL191). Arzneimittel-Forschung 22: 994–999, 1972
Jovanović UJ. Statistical evaluation of polygraphic investigations of pentoxifylline. Journal of International Medical Research 4: 211–222, 1976
Juhan I. Déformabilité des hématies chez les diabétiques. Nouvelle Presse Médicale 7: 759, 1978
Kappert A. Therapeutic experience with a Theologically active agent in an angiologic clinic. Pharmatherapeutica 2(Suppl. 1): 74–81, 1978
Katsunuma H. The influence of pentoxifylline on erythrocyte membrane in aged CVD patients. Proceedings of the 3rd General Meeting of the Japanese Society of Stroke, p. 223, Akita, 1978
Katsunuma H, Imamura T, Ishigaki Y. The clinical efficacy of Trental against various types of cerebrovascular diseases. Journal of New Remedies and Clinics 31: 1845–1851, 1982
Kawagoe Y, Hirata M, Matsubuchi T, Ohkawa H, Nakatsuka S. Inhibitory effects of pentoxifylline on platelet aggregation. Geriatric Medicine 22: 577–583, 1984
Kaznelson LA, Guttoraja EE, Michailova NA, Jakovlev AA, Kaliberdina VF, et al. Experience with pentoxifylline in various vascular disorders of the fundus ocul. Pharmatherapeutica 2: 146–149, 1978
Keller F, Leonhardt H. Amelioration of blood viscosity in sickle cell anemia by pentoxifylline: a case report. Journal of Medicine 10: 429–431, 1979
Kellerhals B. Medikamentose Therapie der Schwerhörigkeit. Therapeutische Umschau 35: 572–577, 1978
Kellner H. Zur Behandlung chronischer arterieller Durchblutungstörungen. Münchener Medizinische Wochenschrift 118: 1399–1402, 1976
Kellner H. Treatment of chronic arterial circulatory disorders: double-blind trial with pentoxifylline (Trental 400). Pharmatherapeutica 3(Suppl. 1): 67–73, 1983
Khosla AA, Chintu C. A pilot study: an open clinical trial of pentoxiphylline in patients with painful sickle cell crises. East African Medical Journal 61: 829–836, 1984
Kiesewetter H, Schneider R, Jurig F, et al. Therapie zerebraler Mikroangiopathien. Untersuchungen mit niedermolekular Hydroxyäthylstärke mit und ohne Pentoxifylline. Therapiewoche 36: 50–55, 1986
Kitatani T, Hayashi S, Sakaguchi T. Effects of pentoxifylline on 5-hydroxy-tryptamine in the mouse brain. Folia Pharmacologica Japonica 86: 353–358, 1985
Knote G, Bohmert H. Viability-test for skin flaps: an experimental and clinical study. Abstract from Third Congress of the International Confederation for Plastic and Reconstructive Surgery, p. 56, 3M Company, The Hague, 1977
Kobaladze SG, Gibradze TA. Einwirkung von Trental (pentoxifylline) auf das experimentell ischämische Myokard. Proceedings of the Van Swieten Congress, pp. 269–270, Vienna, October 1979
Kobaladze SG, Schonia GS. Pentoxifylline and some physicochemical aspects of haemorheology in patients with ischaemic heart disease. Current Medical Research and Opinion 6(Suppl. 4): 5–11, 1979
Kobaladze SG, Tschikvadze IV. The use of pentoxifylline in the treatment of ischaemic heart disease. Current Medical Research and Opinion 6(Suppl. 4): 12–15, 1979
Kobayashi I, Fujita T, Yamazaki H. Platelet aggregability measured by screen filtration pressure method in cerebrovascular disease 7: 406–409, 1976
Koller REB, Cohen MM. The effect of pentoxifylline pretreatment on in vitro cerebral metabolism in the gerbil. Presentation for Ph.D. thesis in pharmacology, University of Illinois, 1976
Komarek Von J, Hüsselrath A, Just M. Effect of pentoxifylline on cerebral blood flow and metabolism in dogs. Arzneimittel-Forschung 27: 1939–1942, 1977
Konotey-Ahulu FID. The sickle cell diseases: clinical manifestations including the ‘sickle crisis’. Archives of Internal Medicine 133: 13–24, 1974
Koppenhagen K. Cerebral blood flow under hypobaric conditions: effects of pentoxifylline (Trental 400). Pharmatherapeutica 4: 1–5, 1984
Koppenhagen K. Thromboembolie-Prophylaxe mit Trental nach chirurgischen Eingriffen in Brust- und Bauchraum. Satellite symposium. 14 World Congress in Angiology, Munich, July 6–10, 1986
Koppenhagen K, Wenig HG. The effect of pentoxifylline on liver perfusion. Medizinische Klinik 74: 1254–1256, 1979
Koppenhagen K, Wenig HG, Müller K. Measurement of cerebral blood flow following intravenous administration of pentoxifylline (Trental). Current Medical Research and Opinion 4: 521–528, 1977a
Koppenhagen K, Wenig HG, Müller K. The effects of pentoxifylline (Trental) on cerebral blood flow: a double-blind study. Current Medical Research and Opinion 4: 681–687, 1977b
Körber N, Schneider R, Brockmann M, Kiesewetter H, Reim M. Retinale Durchblutung bei lakunären infarkten unter therapie mit Pentoxifyllin. Medizinische Welt 37: 1376–1378, 1986
Kostka-Trabkowa E, Demblińska-Kieć A, Grodzińska L, Bieroń K, Gryglewski RJ. Beneficial results of pentoxifylline (Trental) therapy in arteriosclerosis obliterans: possible mechanism of action. Current Medical Research and Opinion 9: 407–416, 1985
Koul BL, Nordhus O, Sonnenfeld T, Ekeström S. The effect of pentoxifylline on impaired red cell deformability following open-heart surgery. Scandinavian Journal of Thoracic and Cardiovascular Surgery 18: 129–131, 1984
Kovaleva LG, Sedova GT, Krasynkova LJ. Preventive correction of hemostasis in polycythaemia vera patients. Gematologiya I Transfuziologiya: 31: 28–32, 1986
Kramer JJ, Swislocki NI. Effects of pentoxifylline on membrane protein phosphorylation in rat erythrocytes. Vascular Medicine 1: 159–173, 1983
Küchle HJ, Richard G. The effect of pentoxifylline on circulatory disturbance of the retina and optic nerve: a report of ten years clinical experience. Ricerca Clinica e in Laboratoria 11(Suppl. 1): 33, 1981
Kuzuya F. Influence of pentoxifylline (Trental) on platelet aggregation. Gendai no Shinryo 19: 1567–1570, 1977
Kuzuya F. The influence of pentoxifylline (Trental) on erythrocyte deformability — a new method for determining erythrocyte deformability. Gendai no Shinryo 20: 575–578, 1978
La Celle PL. Pathologic erythrocytes in the capillary microcirculation. Blood Cells 1: 269–284, 1975
Lagrue G, Gumpelson A, Kamalodine T, Berge D. Effets de la pentoxifylline sur les modifications microcirculatoires au cours des arteriopathies (hypertension artérielle, diabète). Semain Hôpital Paris Therapeutique 53: 441–444, 1977
Lechner H, Ott E. Klinische Bedeutung von Blutviskositätsveränderungen im Rahmen der zerebrovaskulären Insuffizienz. Münchener Medizinische Wochenschrift 117: 1599–1602, 1975
Lechner H, Ott E. Konservative Therapie der cerebrovaskulären insuffisienz. Nervenheilkunde 1: 51–58, 1982
Lechner H, Ott E, Fazekas F. Cerebrovascular disease: where are we now? In Gotoh & Lechner (Eds). Clinical Haemorheology: a new approach to cerebrovascular disease, pp. 11–18, Royal Society of Medicine, London, 1986
Lecomte M-C, Boivin P. Effects of methylxanthine derivatives on red cell phosphorylation. Scandinavian Journal of Clinical and Laboratory Investigations 41(Suppl. 156): 291–295, 1981
Le Devehat C, Lemoine A, Cirette B, Ramet M. Pharmacological influences of pentoxifylline on red cell filterability and 2–3, diphosphoglycerate. Scandinavian Journal of Clinical and Laboratory Investigations 41(Suppl. 156): 301–303, 1981
Lee BY, Berkowitz P, Savitsky JP, May GS, Brobst T, et al. Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease. Clinical Cardiology 8: 161–165, 1985
Lee MM, Hong KP, Oh BH, Choi YS, Seo J, et al. A clinical study on pentoxifylline (Trental) in the treatment of cerebrovascular disease. Korean Circulatory Journal 12: 51–55, 1980
Lehrach F, Grigoleit HG. The flow properties of whole blood under physiological and pathological conditions: microrheo-logical investigation. Current Medical Research and Opinion 6(Suppl. 4): 49–56, 1979
Lehrach F, Müller R. Ergebnisse der klinischen Prüfung des Vasotherapeutikums 3,7-Dimethyl-l-(5-Oxohexyl)-xanthin. Arzneimittel-Forschung 21: 1171–1173, 1981
Lehrach F, Müller R, Theis H. Fünf Jahre klinisch-experimentelle und therapeutische Erfahrungen mit Pentoxifyllin. Medizinische Monatsschrift 31: 159–163, 1977
Lehrach F, Grigoleit HG. The flow properties of whole blood under physiological and pathological conditions: microrheological investigations. Current Medical Research and Opinion 6(Suppl. 4): 49–56, 1979
Lenti G, Pagano G, Angotzi G, Basetti Sani A, Diana A. Effects of xanthine derivative (BL191) on insulin secretion in normal man. European Journal of Clinical Pharmacology 9: 189–192, 1975
Leonhardt H, Grigoleit HG. Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn-Schmiedeberg’s Archives of Pharmacology 299: 197–200, 1977
Leonhardt H, Grigoleit HG, Reinhardt I. Erythrocyte deformability in a red-cell ageing model. Ricerca in Clinica e in Laboratorio 8: 65–71, 1978
Leskovac V, Pericin D. Interaction of pentifylline with mitochondria. Acta Pharmacologia Jugoslavia 30: 23–30, 1980
Lopatkin NA, Darenkov AF, Maso EB, Jarmohinskij IS. The use of pentoxifylline in urological disorders. Pharmatherapeutica 2(Suppl. 1): 131–133, 1978
Lopatkin NA, Ter-Ovanessov GV. The effect of pentoxifylline on oxygen tension in renal tissue: experimental investigations. Pharmatherapeutica 2(Suppl. 1): 129–130, 1978
Lorient MF, Boisseau MR, Bricand H, Manuau JP, Auière C. Réduction de la filtrabilité érythrocytaire et accidents vasculaires cérébraux. Semaine de Hôpitaux de Paris, 55: 1–3, 1979
Lowenstein PR, Vacas MI, Cardinali DP. Effect of pentoxifylline on α- and β-adrenoceptor sites on cerebral cortex medial basal hypothalamus and pineal gland of the rat. Neuropharmacology 21: 243–248, 1982
Lucas MA. Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology 35: 443–450, 1984
Lusov VA, Belousov JB, Sidelmann AA, Savenkov MP, Cholodova OE, et al. The treatment of peripheral atherosclerosis with pentoxifylline. Pharmatherapeutica 2(Suppl. 1): 123–128, 1978
Maak G. Ambulante Hörsturztherapie mit Dextran und Pentoxifylline. Therapiewoche 36: 3347–3351, 1986
Maass B, Ludwig D. Effect of pentoxifylline (Trental) on cochlear blood flow as measured by hydrogen wash-out. Current Medical Research and Opinion 9: 52–55, 1984
Macchione C, Molaschi M, Neirotti M, Garrone MT, Longo F, et al. Modificazioni emereologiche, emocoagulative e fotopletismografiche indotte dalla somministrazione di pentossifilline in soggetti con mallattic di Raynaud. Minerva Medica 76: 1401–1405, 1985
Markl H, Niemeier H. Haemorheologische Therapie der peripheren arteriellen Versehlusskrankheit, Ergebnisse einer Feldstudie mit Trental forte. Praktische Arzt 35: 1825–1836, 1981
Mahicovsky NN, Vinnizkij LJ, Fjodorov NA, et al. Some aspects of the potential clinical uses of pentoxifylline. Pharmatherapeutica 2(Suppl. 1): 36–41, 1978
Manrique R. Clinical and laboratory evaluation on the modification of erythrocyte flexibility induced by pentoxifylline. Revista Brasileira de Clinica e Terapeutica 8: 572–578, 1979
Manrique R. Importance of rheological factors in the evolution of myocardial infarction. Abstract No 740, p. 205, Abstract Volume II, IX World Congress of Cardiology, Moscow, June 20–26, 1982
Manrique R. Blood coagulation, Theology and coronary reocclusion after local thrombolysis in myocardial infarction. Abstract Volume XII World Congress, International Union of Angiology, Rochester, Minnesota, USA, Sept 11–16, 1983
Manrique R, Manrique V. Primary prevention of atherosclerosis at high altitude. In Lenzi & Descovich (Eds) Atherosclerosis and cardiovascular diseases, pp. 63–67, Editrice Compositori, Bologna, 1984
Marcel GA. Red cell deformability: physiological, clinical and pharmacological aspects. Journal of Medicine 10: 409–416, 1979
Marcel GA, Lagrue G. La déformabilité érythrocitaire. Nouvelle Presse Medicale 8: 4077–4078, 1979
Marrama P, Baraghini GF, Carani C, Celani MF, Giovenco P, et al. Further studies on the effects of pentoxifylline on sperm count and sperm motility in patients with idiopathic oligo-asthenozoospermia. Andrologia 17: 612–616, 1985
Marsiglia EAP, Santillan Eld J. Pentoxifylline treatment of asthenozoospermia. Andrologia 15: 571–572, 1983
Martin P, Vives P. Déformabilité des globules rouges et accidents vasculaires cérébraux: intérêt de la pentoxifylline. Gazette Médicale de France 86: 2585–2587, 1979
Martin P, Vives P. The effect of pentoxifylline on red cell deformability in cerebrovascular accidents. Current Medical Research and Opinion 6: 518–522, 1980
Masowezkij AG, Stoilov LD, Kukashina TV, Tirkina TN, Titova SI. The use of pentoxifylline in diabetes mellitus. Pharmatherapeutica 2(Suppl. 1): 105–108, 1978
Matrai A, Ernst E. Pentoxifylline improves white cell rheology in claudicants. Clinical Hemorheology 5: 483–491, 1985
Mattem H, Niemeier H. Enhanced blood circulation as a result of improved microcirculation. Ärztliche Praxis 31: 2638–2640, 1979
Matzky R, Darius H, Schrör K. The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue. Arzneimittel Forschung/Drug Research 32: 1315–1318, 1982
Maxwell GM. The effects of a new xanthine derivative, 3,7-dimethyl-1-(5-oxohexyl)-xanthin (pentoxifylline) on the general and cardiac haemodynamics of the intact animal. Ajebak 53: 265–271, 1975
Mayer H, Grunau G, Spoors KH. Behandlung arterieller und arterio-venöser Durchblutungsstörungen mit Trental. Therapiewoche 25: 4941–4949, 1975
M’Bensa A. Intérêt de la pentoxifylline dans le traitement de la drépanocytose. Médecine d’Afrique Noire 30: 480–484, 1983
McDowell FH. Cerebrovascular diseases in Beesan et al. (Eds) Textbook of medicine, pp. 777–801, W.B. Saunders Company, Philadelphia, 1979
McMillan DE, Utterback NG, La Puma J. Reduced erythrocyte deformability in diabetes. Diabetes 27: 895–901, 1978
Menon AD. Clinical experience with pentoxifylline in the treatment of peripheral vestibular diseases — Results of a cooperative study. Revista Brasiliera de Medicina 38: 630–634, 1981
Metoki H, Kudo R, Shimanaka Y, Matsui T, Kanazawa T, et al. A study on blood viscosity in cerebrovascular disease. Hirosaki Medical Journal 35: 1–10, 1983
Mevio E, Galioto P. Proposta di assozione therapeutica emodilusione-pentossifillina nelle labirintopatie vascolari. Ricerca Clinica e in Laboratorio 15(Suppl. 1): 547–552, 1985
Michal M, Giessinger N. The effect of pentoxifylline on thrombus formation in vivo. Abstract No. 565, 9th International Congress of Pharmacology, July 29–Aug 3, London, 1984
Micic DV, Stefanovich V, Mrsulja BB. The effect of pentoxifylline on cytotoxic form of ischemic brain edema in mongolian gerbil. IRCS Med Sci 9: 709, 1981
Mihajlović D, Hadzi-Pesić L, Marković V, Lović B, Cirić D, et al. Experiences with pentoxifylline in the treatment of peripheral vascular disease. Current Medical Research and Opinion 6(Suppl. 4): 43–48, 1979
Monteiro DT, Santamore WP, Nemir P. The influence of pentoxifylline on skin-flap survival. Plastic and Reconstructive Surgery 77: 277–281, 1986
Moratti F, Cortiana M, Taglioretti D. Applicazione della filtrazione eritrocitaria nello studio della vasculopatia diabetica: efficacia terapeutica della pentossifillina. Clinica Terapeutica 106: 19–25, 1983
Motais R. Lack of effect of pentoxifylline on chloride and glucose permeability in human red cells. Scandinavian Journal of Clinical and Laboratory Investigations 41(Suppl. 156): 281, 1981
Muggeo M, Calabro A, Businaro V, Patussi L, Volpe A, Signorini GP, Crepaldi G. Blood clotting, fibrinolytic and haemorheological parameters in ischaemic vascular disease: the effects of pentoxifylline in the treatment of acute cerebral vascular disease. Pharmatherapeutica 3(Suppl. 1): 74–90, 1983
Müller R. Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Current Medical Research and Opinion 6(Suppl. 4): 15–24, 1979a
Müller R. Pentoxifylline — a biomedical profile. Journal of Medicine 10: 307–329, 1979b
Müller R. Hemorheology and peripheral vascular diseases: a new therapeutic approach. Journal of Medicine 12: 209–235, 1981
Müller R. On the therapy of disturbances of blood fluidity. Angiology 36: 226–234, 1985
Müller R, Lehrach F. Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline. Pharmatherapeutica 2: 372–379, 1980
Müller R, Lehrach F. Haemorheology and cerebrovascular disease: multi-functional approach with pentoxifylline. Current Medical Research and Opinion 7: 253–263, 1981
Müller R, Lehrach F, Grigoleit HG. Zum Wirkungsmechanismus von Pentoxifyllin. Medizinische Monatsschrift 29: 487–491, 1975
Müller R, Mušikić P. Haemorheology in surgery — a review. Angiology, in press, 1987
Mund-Hoym WD. The treatment of chronic arterial blood circulation interference. Schweizerische Rundschau für Medizin 67: 1593–1599, 1978
Muratore F. The use of pentoxifylline in the treatment of torpid ankle ulcers in thalassaemia major. Clinica Terapeutica 101: 493–495, 1982
Muruyama M. Ex vivo human platelet aggregation induced by decompression during reduced barometric pressure, hydrostatic, and hydrodynamic (Bernoulli) effect. Thrombosis Research 33: 477–485, 1984
Najdanović B, Zdravković M, Korolija P, Popović D. Experience with pentoxifylline in the treatment of peripheral arterial disease. Pharmatherapeutica 2(Suppl. 1): 94–99, 1978
Nakao M, Nakao T, Yamazoe S. Adenosine triphosphate and maintenance of shape of human red cells. Nature 187: 945–946, 1960
Nardini M, Passero S, Battistini N, Fieschi C. Pathophysiology of cerebral blood flow in brain ischemia. Ricerca in Clinica e in Laboratoria 11(Suppl. 1): 233–242, 1981
Neirotti M, Longo F, Molaschi M, Macchione C, Pernigotti L. Functional vascular disease: treatment with pentoxifylline. Angiology 37: 397, 1986
Nejmark MJ. Disorders of hemocoagulation and fibrinolysis in patients with chronic renal failure during treatment with haemodialysis and approaches to its correction. Teraperticheskii Arkhiv (Moskva) 53: 48–53, 1984
Nenci GG, Gresele P, Agnelli G, Ballatori E. Effect of pentoxifylline on platelet aggregation. Pharmatherapeutica 2: 532–538, 1981
Ng RP, Tse TF, Chan TK. Platelet survival in patients with artificial heart valves and the effect of anti-platelet agents. Singapore Medical Journal 20(Suppl. 1): 30–37, 1979
Ngandu-Kabeya D. Interêt d’un medicament augmentant la déformabilité des globules rouges (pentoxifylline-Torental) dans le traitement de la drepanocytes. Médecine d’Afrique Noire 30: 431–434, 1983
Nishio T, Toshima Y, Matsuno Y. Effects of pentoxifylline on cell shape, ATP content and deformability in rabbit erythrocytes under hyperosmolar conditions. International Journal of Biochemistry 14: 915–920, 1982
Nolte D. Lungenfunktionsuntersuchungen zur bronchospasmolytischen Wirkung von 3,7-Dimethyl-l-(5-Oxo-hexyl)-Xanthin. Arzneimittel-Forschung 21: 1453, 1971
Nordhus O, Ekeström S, Liljeqvist L. Effects of pentoxifylline on central haemodynamics in patients with congestive heart failure. Scandinavian Journal of Thoracic and Cardiovascular Surgery 20: 217–220, 1986
Nüdemberg F, Chamberlain J, Hajdu P, Uihlein M, Müller R. Influence of intravenously administered pentoxifylline on endogenous secretion of catecholamines. IRCS Medical Science 10: 466–467, 1982
Ohshima N, Sato M. Effect of pentoxifylline on microvascular blood flow velocity. Angiology 32: 752–763, 1981
Olivari N, Olivari B. Beeinflussung der Lappendurchblutung und Nekroserate nach Verschiebeschwenkplastik durch Pentoxifyllin und Dextran 40. Medizinische Welt 26: 1973–1975, 1975
Orlando E, Pierangeli A, Coli G, Palareti G, Poggi M, et al. Azione della pentossifillina sulla velocità del angue aortico nella stenosi valvolare dell’aorta. Minerva Cardioangiologica 31: 529–534, 1983
Ott A. Transkutane pO2 Messung in der Dermatologie. In Ehrly et al. (Eds) Klinische Sauerstoffdruckmessung, pp. 145–150, MWP, München, 1985
Ott E. The clinical importance of haemorheological alteration in cerebrovascular disease. In Gotoh & Lechner (Eds). Clinical Haemorheology: a new approach to cerebrovascular disease, pp. 25–32, Royal Society of Medical Services, London, 1986
Ott E, Bertha G, Ladurner G, Marko P, Lechner H. Möglichkeiten und Grenzen der Behandlung zerebrovaskulärer Risikofaktoren. Der Praktische Arzt 34: 187–192, 1979
Ott E, Fazekas F, Lechner H. Haemorheological effects of pentoxifylline in disturbed blood flow behaviour in patients with cerebrovascular disease. European Neurology 22(Suppl. 1): 105–107, 1983
Ott E, Fazekas F, Valetitsch H, et al. The rationale of rheological pharmacological therapy. Clinical Hemorheology 6: 35–40, 1986
Ott E, Lechner H. Changes of flow properties of the blood in cerebrovascular disease and their medical treatment with pentoxifylline. Journal of Cerebral Blood Flow and Metabolism 3(Suppl. 1): 530–531, 1983
Ott E, Lechner H, Aranibar A. High blood viscosity syndrome in cerebral infarction. Stroke 5: 330–334, 1974
Ott E, Lechner H, Bertha G, Margue K, Aranibar A, et al. Evaluation and laboratory controlled treatment of increased platelet aggegation in patients with cerebrovascular disease. Proceedings of the 10th Salzburg Conference in Cerebrovascular Disease, pp. 40–48, Excerpta Medica, Amsterdam, 1981
Palareti G, Coccheri S, Poggi M, Tricarico MG, Magelli M, et al. Changes in the rheologic properties of blood after a high altitude expedition. Angiology (July): 451–458, 1984
Pallestrini EA, Bastiani G, Benedetti G. Esperienze terapeutiche con pentossifillina nella ipoacusia neurosensoriale e nella malattia di ménière. Ricerca in Clinica e in Laboratoria 11(Suppl. 1): 395–407, 1981
Parnetti L, Ciuffetti G, Mercuri M, et al. The role of haemorheological factors in the ageing brain: long-term therapy with pentoxifylline (Trental 400) in elderly patients with initial mental deterioration. Pharmatherapeutica 4: 617–627, 1986
Parnetti L, Ciuffetti G, Mercuri M, Senin U. Haemorheological pattern in initial mental deterioration: results of a longterm study using piracetam and pentoxifylline. Archives of Gerontology & Geriatrics 4: 145–155, 1985
Parrozzani A, Fedriga P. The action of oxpentifylline on the central fusion frequency in subjects with chronic ischaemic maculopathy. Minerva Oftalmologica 24: 141–148, 1982
Passero S, Nardini M, Battistini M. Effect of pentoxifylline on cerebral blood flow in patients with chronic cerebrovascular disease. Journal of International Medical Research 9: 211–214, 1981
Pecker J, Vallée B, Haranger J-M, Gueguen M. Torental et accidents ischémiques du système nerveux central. L’Ouest Medical 31: 1571–1574, 1978
Pemler K, Penth B, Adams HJ. Pentoxifyllin-Medikation im Rahmen der Ulcus cruris-Behandlung. Ergebnisse einer Feldstudie mit Trental 400. Fortschritte der Medizin 97: 1019–1022, 1979
Perego MA, Sergio G, Artale F. Haemorheological aspects of the pathophysiology and clinical features of peripheral occlusive arterial disease. Pharmatherapeutica 3(Suppl. 1): 91–101, 1983
Perego MA, Sergio G, Artale F, Giunti P, Danese C. Haemorheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Current Medical Research and Opinion 10: 135–138, 1986
Perhoniemi V, Salmenkivi K, Sundberg S, Johnsson R, Gordin A. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology 35: 366–372, 1984
Petelin LS, Stock VN, Smirnov JD, Pigarev WA, Fjodorova NV, et al. Pentoxifylline in the neurological clinic. Pharmatherapeutica 2(Suppl. 1): 141–145, 1978
Petruzzi E, Bucalossi A, Corri S, Marsilii A, DiNoto C. L’uso della pentossifillina nei diabetici con claudicatio infernilbeus. Ricerca Clin Lab 13(Suppl 3): 451–454, 1983
Pettegrew J, Kopp S, Glonek T. P-31 nuclear magnetic resonance study of pentoxifylline effect on experimental cerebral ischemia. Neurology 33(Suppl. 2): 152, 1983
Pignoli P, Ciccolo F, Villa V, Longo T. Comparative evaluation of buflomedil and pentoxifylline in patients with peripheral arterial occlusive disease. Current Therapeutic Research 37: 596–606, 1985
Pilla G, Ciaponi A, Migliavacca A, Bonora C. L’insufficienza cerebrovascolare cronica senile. Effetti del suloctidil e della pentossifillina sulla deformabilita eritrocitaria. La Ricerca Clinica e in Laboratorio 13(Suppl 3): 459–464, 1983
Pilotovich VS, Kozlov GT, Tukai NI, Kharchenko AS, Ivanova NS, et al. Possibilities of conservative therapy of chronic renal insufficiency. Ter. Arkh 54: 79–82, 1982
Piras AF. Pentoxifylline in the treatment of chronic hypoacousias: a clinical and audiometric study. Pharmatherapeutica 2: 216–221, 1979
Pitel JA, Solotarjov II, Volkov VS, Sereda IV, Djakonov VP. Pentoxifylline in the combination therapy of pyelonephritis. Pharmatherapeutica 2(Suppl. 1): 138–140, 1978
Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GGN. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis. Angiology 36: 628–636, 1985
Pohanka E, Sinzinger H. Effect of a single pentoxifylline administration on platelet sensitivity, plasma factor activity, Plasma 6-oxo-PGF1α and Thromboxane B2 in healthy volunteers. Prostaglandines Leukotrienes and Medicine 22: 191–200, 1986
Popendiker U, Boksay I, Bollmann V. Zur Pharmakologie des neuen peripheren Gefassdilatators 3,7-dimethyl-l-(5-oxohexyl)-xanthin. Arzneimittel Forschung 21: 1160–1171, 1971
Porsche E, Stefanovich V. The effect of pentoxifylline on ATPase activity of human erythrocyte membranes. IRCS Medical Science 6: 285, 1978
Porsche E, Stefanovich V. The influence of pentifylline and theophylline on reaction kinetics on rat brain ATPase stimulable by catecholamines. Arzneimittel-Forschung 29: 1089–1092, 1979
Porter JM. Pharmacologic approaches to intermittent claudication and vasospasm. In Spittell (Ed.) Pharmacologic approach to the treatment of limb ischemia, pp. 179–195, College of Physicians of Philadelphia, Philadelphia, 1983
Porter JM, Cutler BC, Lee BY, Reich T, Reichle FA, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. American Heart Journal 104: 66–72, 1982
Pricladnitzki A. Use of a new vasoactive drug in geriatric patients with cerebral circulatory insufficiency. Revista Brasileira de Medicina 36: 309–314, 1979
Pupita F, Rotatori P, Frausini G. Farmacologia clinica delle sostanze vasoattive: studi sulla pentossifilline. Ricerca in Clinica e in Laboratoria 11(Suppl. 1): 293–302, 1981
Pupita F, Rotatori P, Frausini G. Clinical pharmacology of vasoactive drugs: studies on pentoxifylline. Pharmatherapeutica 3(Suppl. 1): 102–110, 1983
Pyrochkin VM, Baranovsky PA, Fadeev GI. The effect of pentoxifylline on haemodynamic indices and tolerance to physical load in the treatment of patients with IHD (Russ). Zdravoochranenie Belorussii (Minsk) 29: 23–26, 1983
Queiroz Maudonnet OA. Double-blind clinical trial with BL-191 3,7-Dimethyl (l-(5’-oxohexil)-3,7-dimetilxantine) in the treatment of patients bearing a peripheric vestibular syndrome of vascular etiology. Revista Brasileira de Medicina 34: 95–99, 1977
Radmilovic A, Boric Z, Naumovic T, et al. Shunt thrombosis prevention in haemodialysis patients — double blind controlled study pentoxifylline versus placebo. Angiology 37: 395, 1986 Raithel D, Kasprzak P. Prevention of reocclusion after synthetic prosthetic bypass–operations in femoropopliteal area: comparative randomized study of pentoxifylline versus acetylsalicylic acid. Angiology 36: 678, 1985
Raptis S. A clinical-pharmacologic study of the effect of pentoxifylline on hormone secretion in man. Journal of Medicine 10: 381–407, 1979
Redmayne GN, Aves EK, Sanford J. The comparative effects of three vasoactive compounds (oxpentifylline, prazosin and indorman) on the blood rheology of beagle dogs. Clinical Hemorheology 5: 301–309, 1985
Reid HL, Barnes AJ, Lock PJ, Dormandy JA. A simple method for measuring erythrocyte deformability. Journal of Clinical Pathology 29: 855–858, 1976b
Reid HL, Dormandy JA, Barnes AJ, Lock PJ, Dormandy TL. Impaired red cell deformability in peripheral vascular disease. Lancet 2: 666–667, 1976a
Rizzo G, Ariano R. Nuovi criteri terapeutici in corso du vasculopatie cerebrali croniche diffuse. Policlinico Sezione Medica 86: 147–153, 1979
Robin JC, Ambrus JL. Studies on osteoporoses. XI. Effects of a methyl-xanthine derivative. Journal of Medicine 14: 137–145, 1983
Robin JC, Ambrus JL. Study of antiosteoporotic agents in tissue culture. Journal of Medicine 15: 319–322, 1984
Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 35: 396–406, 1984
Ruberti U, Morbidelli A. Ruolo e possibile controllo dei fattori di rischio nell vasculopatie artersclerotiche per la valutazione dei risultati del trattamento chirurgico: studio preliminare sull’ impiego dell pentossifillina. Ricerca in Clinica e in Laboratorio 11(Suppl. 1): 387–394, 1981
Rudofsky G, Brock FE, Ulrich M, Nobbe F. The effect of pentoxifylline on haemodynamic and ergometric variables in patients with arterial occlusive disease (Stage II). Pharmatherapeutica 3(Suppl 1): 111–116, 1983
Sakaguchi T, Hayashi S. Pharmacology and clinical trials of pentoxifylline. Pharmacometrics 15: 153–183, 1978
Sakai T, Okada J, Hara M, Ogashiwa M, Takeuchi K. Red cell deformability in patients with cerebral vasospasm. International Journal of Clinical Pharmacology, Therapy and Toxicology 23: 79–82, 1985
Sakurai M, Komine I, Goto M. Protective effect of pentoxifylline on experimental thrombosis induced by stenosis of femoral artery in rabbits. Japanese Pharmacology and Therapeutics 13: 5–138, 1985
Sakuta S, Takamatsu S, Satoh K, Mizuno S, Metoki H. Deformability of erythrocyte in cerebrovascular disorders. Acta Neurologica Scandinavica 60(Suppl. 72): 614–615, 1978
Saldan IR. The usage of disaggregants for the treatment of diabetic retinopathy. Oftal’mologicheskii Zhurnal 7: 395–398, 1984
Satewachin II, Iljin VN, Schestakov VA, Alexandrova NP, Rodionov SV, et al. The use of pentoxifylline in a combined regimen for the prevention of re-thrombosis in major blood vessels. Pharmatherapeutica 2: 109–117, 1978
Sauer GS. Pentoxifylline (Trental) therapy for the vasculitis of atrophic blanche. Archives of Dermatology 122: 380–381, 1986
Schade UF, Schönharting M. Effects of pentoxifylline on the endotoxin induced shock reaction. Clinical Hemorheology 6: 462, 1986
Schaefer K, von Herrath D, Hensel A, Grigoleit H-G. Untersuchungen zur Pharmacokinetik von Pentoxifyllin bei chronischer Niereninsuffizienz. Medizinische Klinik 72: 204–206, 1979
Schafé MK. Erfahrungen mit Trental bei peripheren Druchblutungsstörungen und zerebrovaskulärer Insuffizienz. Münchener Medizinische Wochenschrift 115: 1745–1749, 1973
Schatilova TA, Aleksidse TA, Kandelaki DM, Kvaliaschwili MA, Mschvidobadze EG, et al. Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. Current Medical Research and Opinion 6(Suppl. 4): 30–34, 1979
Schill WB. Therapie der idiopathischen Aestheno- und Oligozoospermie mit Pentoxifyllin. Fortschritte der Medizin 100: 696–700, 1982
Schindler H. Pentoxifyllin und seine klinische Anwendung bei Durchblutungsstoerungen. Therapiewoche 28: 1294–1304, 1978a
Schindler H. Clinical use of pentoxifylline. Pharmatherapeutica 2(Suppl. 1): 66–73, 1978b
Schmalzer EA, Chien S. Filterability of subpopulations of leukocytes: effect of pentoxifylline. Blood 64: 542–546, 1984
Schmid-Schönbein H, Volger E. Red-cell aggregation and red-cell deformability in diabetes. Diabetes 25: (Suppl. 1): 897–902, 1976
Schmid-Schönbein H, Weiss J, Ludwig H. A simple method for measuring red cell deformability in models of the microcirculation. Blut 26: 369–379, 1973
Schmid-Schönbein H, Wells R, Goldstone J. Influence of deformability of human red cells upon blood viscosity. Circulation Research 15: 131–143, 1969
Schneider R, Brockmann M, Kiesewetter H, et al. Behandlung lakunärer Infarkte mit Pentoxifyllin. Medizinische Welt 37: 1340–1343, 1986
Schneider R, Schmid-Schoenbein H, Kiesewetter H. The rheological efficiency of parenteral pentoxifylline (Trental) in patients with ischemic brain lesions. European Neurology 22(Suppl. 1): 98–104, 1983
Schramm P, Hinze HJ. Die Konzentration von Pentoxifyllin bei oraler Gabe in Seminalplasma. Andrologia 12: 482–484, 1980
Schreiber P, Schröppel M, Heidrich H. Effects of naftidrofuryl, pentoxifylline and bencyclane on the renal blood flow and renal excretion of conscious dogs. Herz 15: 195–201, 1983
Schrör K, Matzky R, Kahlen T, Darius H. The release of prostacyclin by pentoxifylline from human and animal vascular tissue and its implications for vascular and antiplatelet activities. Thrombosis and Haemostasis 46: 272, 1981
Schrör RH. Antithrombotic potential of pentoxifylline — a hemorheologically active drug. Angiology 36: 387–398, 1985
Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica 1: 172–179, 1976
Schubotz R, Mühlfellner O. The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane. Current Medical Research and Opinion 4: 609–617, 1977
Schultheiss R, Leuwer R, Leniger-Follert E, Wassmann H, Wüllenweber R. Tissue PO2 of human brain cortex-method, basic results and effects of pentoxifylline. Angiology 37: 398, 1986
Schulz CEJ, Richter W, Naujoks J. Blutviskosität und Innenohrschwerhörigkeit. Laryngologie, Rhinologie, Otologie 56: 328–334, 1977
Seiffge D. Effect of pentoxifylline on red cell aggregation (RCA). IRCS Medical Science 8: 727, 1982
Seiffge D. Micro mechanical methods to determine haemorheological parameters. Acta Medica Portuguesa 6: 523–526, 1985
Seiffge D, Berthold R, Berthold F. Effect of pentoxifylline on sickle cell thalassaemia: haemorheological and clinical results. Klinische Wochenschrift 16: 1159–1160, 1983
Seiffge D, Kiesewetter H. Effect of pentoxifylline on single red cell deformability. Klinische Wochenschrift 59: 1271–1272, 1981a
Seiffge D, Kiesewetter H. Filterability investigations with red blood cell (RBC) suspensions: effects of different blood components and pentoxifylline on RBC flow rate. Ricerca in Clinica e in Laboratory 11(Suppl. 1): 117–123, 1981b
Seiffge D, Kremer E. Antithrombotic effects on pentoxifylline on laser-induced thrombi in rat mesenteric arteries. IRCS Medical Science 12: 91–92, 1984
Semler P, Werner U. Diabetes mellitus und Mikrozirkulation. Fortschritte der Medizin 94: 354–357, 1976
Sen S, Chakravarty A. Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. Angiology 28: 340–345, 1977
Sinzinger H. Pentoxifylline enhances formation of protacyclin from rat vascular and renal tissue. Prostaglandins Leukotrienes and Medicine 12: 217–226, 1983
Sirs JA. Erythrocyte flexibility and metabolism. Biorheology 15: 53–54, 1978
Slijepcevic D, Devecerski M. The use of pentoxifylline in insulin dependent diabetics, with late complications. Current Medical Research and Opinion 6(Suppl. 4): 37–42, 1979
Smith RV, Waller ES, Doluisio JT, Banzer MT, Puri SK, et al. Pharmacokinetics of orally administered pentoxifylline in humans. Journal of Pharmaceutical Sciences 75: 47–52, 1986
Smud R, Sermukslis B, Kartin D. Changes in blood viscosity induced by pentoxifylline. Pharmatherapeutica 1: 229–233, 1976
Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte filtrability: results of a 2 year follow-up study with pentoxifylline. Pharmatherapeutica 4: 341–350, 1985
Solerte SB, Fioravanti M, Bozzetti A. Pentoxifylline, albumin excretion rate and proteinuria in type I and II diabetic patients with microproteinuria. Results of a short term randomised study. Acta Diabetologica Latina 23: 171–176, 1986
Somlo T, Arnold W. Aremerkungen zur Therapie der idiopathischen Facialisparese. In Kellerhals B et al. (Eds) Problemes actuels d’otorhinolaryngologie, pp. 51–59, Huber, Bern, 1984
Sowemimo-Coker SO, Turner P. The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells. European Journal of Clinical Pharmacology 29: 55–59, 1985
Specivzeva VG, Kasabjan IN, Mamaeva GG, Kukes VG. Treatment of microcirculation disorders with Trental and Complanum in patients with diabetes mellitus. Sovetskaja Medicina 2: 64–69, 1980
Spriet A, Beiler D, Dechorgnat J, Simon P. Adherence of elderly patients to treatment with pentoxifylline. Clinical Pharmacology and Therapeutics 27: 1–8, 1980
Stauch M, Richter P, Roth J, Herrmann T, Schmutz C, et al. Kardiale Wirkung von Pentoxifyllin bei Patienten mit Koronarer Herzerkrankung in Ruhe und während Belastung. Herz/Kreislauf 18: 489–495, 1986
Steen PA, Michenfelder JD. Pentoxifylline does not protect mice against hypoxia. Acta Anaesthesiologia Scandinavica 25: 169–170, 1981
Steen PA, Milde JH, Michenfelder JD. Pentoxifylline does not change cerebral blood flow or metabolism in the dog. Acta Anaesthesiologia Scandinavica 25: 319–322, 1981
Steen PA, Milde JH, Michenfelder JD. Pentoxifylline in regional cerebral ischemia in cats. Acta Anaesthesiolgia Scandinavica 26: 39–43, 1982
Stefanović S, Mićić J, Durić D, Manojilović D, Jančić M, et al. Uticay Trentala na metabolizam lipida i agregaciju trombocita u dijabetes melitusu. Proceedings of the 3rd Jugoslavian Symposium for Diabetes, 13–16 October, Zagreb, 1977
Stefanovich V. The biochemical mechanism of action of pentoxifylline. Pharmatherapeutica 2(Suppl. 1): 5–16, 1978
Stefanovich V, Jarvis P, Grigoleit H-G. The effect of pentoxifylline on the 3’5’ cyclic AMP-system in bovine platelets. International Journal of Biochemistry 8: 359–364, 1977
Stefanovich V, John JP. Influence of pentifylline on brain metabolism of normal and anoxic rats. Arzneimittel-Forschung 28: 2097–2099, 1978
Stefanovich V, Macukat M, Hunn G. Effect of pentoxifylline on brain adenine nucleotide levels in anoxic rats. IRCS Medical Science 4: 506, 1976
Stefanovich V, Porsche E, Müller E. On the influence of pentoxifylline on the permeability of rat erythrocytes for methyl-0-glucose. Arzneimittel-Forschung 29: 757–760, 1979
Sternitzky R, Seige K. Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. Current Medical Research and Opinion 9: 602–610, 1985
Stennert E. Bell’s palsy — a new concept of treatment. Archives of Otorhinolaryngology 225: 265–268, 1979
Stennert E. Pathomechanisms in cell metabolism: a key to treatment of Bell’s palsy. Annals Otorhinolaryngol 90: 577–580, 1981
Stömer B. Zur Rheologie des Blutes bei arteriellen Verschlusskrankheiten. Herz Kreislauf 8: 311–320, 1976
Störmer B, Kleinschmidt K, Loose D, Kremer K. Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs. Current Medical Research and Opinion 4: 588–595, 1977
Strano A, Avelone G, Novo S, et al. Modificazioni di alcuni parametri emoreologici in dolte dal trattamento con pentoxifillina in pazienti affelti da progresso infarto del myocard. Ricerca Clin. Lab. 15(Suppl 1): 621–624, 1985
Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 439–446, 1984
Yaya R, Aznar J, Vaya A, Villa P, Santos T, et al. Effect of dipyridamole plus pentoxifylline in patients with diffuse cerebrovascular insufficiency. Thrombosis & Haemostasis 54: 896, 1985
Yoritsune M. Influences of hemorheological factors on CVD patients — with particular reference to RBC deformability. Proceedings of the 3rd General Meeting of the Japanese Society of Stroke, pp. 218, Akita, 1978
Zaccaria A, Autonini M, Marciani A, Taurino M, Speziale F, et al. Valutazione clinica ed emodinamica dell’azione della pentossiflllina nei pazienti con arteriopatia ostruttiva degli arti inferiori. Ricerca in Clinica e in Laboratorio 11(Suppl. 1): 381–386, 1981
Zahavi J, Zelikowski A, Schafer R, Firsteter E, Zahavi M, et al. Efficacy of intravenous pentoxifylline in the management of patients with advanced peripheral vascular disease (PVD). Abstract. International Symposium on Vascular Surgery, Jerusalem, March 23–28, 1986
Zinzadse KI, Gulischwili LN, Tavchelidse TD, Vorobjov OJ. The effect of pentoxifylline on the flow properties of blood in experimental atherosclerosis in rabbits. Pharmatherapeutica 2: 118–122, 1978
Zivkovič R, Mojsilovic L, Kostic M. Effects of pentoxifylline on energy metabolism in washed human erythrocytes. Biomedica Biochimica Acta 43: 76–78, 1984
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: J.L. Ambrus, Roswell Park Memorial Institute, Buffalo, New York, USA; J.A. Dormandy, St James’ Hospital, London, England; A.M. Ehrly, University Medical School, Frankfurt, West Germany; H. Gastpar, Universitäts-Hals-Nasen-Ohrenklinik München, Munich, West Germany; M. Guerrini, Instituto di Patalogia Speciale Medica e Metodologia Clinica dell’Universita Degli Studi di Siena, Siena, Italy; H. Katsunuma, Tokyo Medical College, Tokyo, Japan; J.S. Meyer, Veterans Administration Medical Center, Houston, Texas, USA; J.M. Porter, Oregon Health Sciences University, Portland, Oregon, USA; A. Strano, Istituto di Clinica Medica Generale e Terapia Medica I dell’Università di Palermo Policlinico, Palermo, Italy.
‘Trental’ (Hoechst).
Rights and permissions
About this article
Cite this article
Ward, A., Clissold, S.P. Pentoxifylline. Drugs 34, 50–97 (1987). https://doi.org/10.2165/00003495-198734010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198734010-00003